Eli Lillyの空売り状況は、投資家がEli Lillyの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Eli Lilly (NYSE:LLY) 株価情報, 空売り情報

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

News

Upgrades

Pre-Market Outlook

Analyst Ratings

Trading Ideas

HOOD

TTWO

主要なアナリストが株式レーティングを見直したトピックスを紹介する。アナリストのレーティング変更（格上げ・格下げを含む）はアナリストレーティングのページをご覧いただきたい。

ロビンフッドのアナリスト　市場への評価を変更

Equities

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

Short Sellers

Short Ideas

Eli Lilly and Co (NYSE:LLY) のフロートに対する新しいショート比率は、前回の報告から14.06％上昇しています。同社は最近、ショートで売られた株は616万株あり、これは取引可能なすべての普通株の0.73％に相当します。平均してこの株のショートポジションをカバーするには、トレーダーは2.39日かかります。

イーライリリー社をショート比率から分析

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual return of 14.67%. Currently, Eli Lilly has a market capitalization of $738.30 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $16,007.60 today based on a price of $822.00 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743118208_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Eli Lilly 20 Years Ago Would Be Worth Today

Biotech

General

ONVO

Organovo Says with The Closing Of The Sale Of Its FXR Program To Lilly, It Has Received Upfront Payments And Anticipates Future Milestone Payments

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) has been on a tear in the <a href="https://www.benzinga.com/topic/weight-loss-drug">weight loss drug</a> race, but its stock is slimming down for all the wrong reasons.
Shares have plunged 44.14% over the past year, 17.4% year-to-date, and 19.27% in the last month.
The Novo Nordisk stock fell to a fresh 52-week low of $72.15 — a far cry from its peak of $148.15.
<h2 class="wp-block-heading">NVO Stock Chart: A Bearish Picture</h2>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="631" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM.png" alt="" class="wp-image-843028" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26121310/Screenshot-2025-03-26-at-9.42.58-PM-300x232.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
The stock is firmly in bearish territory, trading below its eight, 20, and 50-day exponential moving averages. It&#8217;s a sign that selling pressure isn't letting up. 
The eight-day simple moving average (SMA) of $77.11, 20-day SMA of $81.23 and 50-day SMA of $82.94 all flash bearish signals, while the 200-day SMA of $111.72 highlights just how deep this decline has been.
Adding insult to injury, the MACD (moving average convergence/divergence) reading of a negative 3.04 and RSI (relative strength index) of 32.37 suggest further downside risk.
Read Also: <a href="https://www.benzinga.com/insights/news/25/03/44474102/if-you-invested-1000-in-this-stock-5-years-ago-you-would-have-this-much-today">If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today</a>
<h2 class="wp-block-heading">A New Obesity Drug Bet: Too Little, Too Late?</h2>
While Novo Nordisk is busy betting on the future with its latest <a href="https://www.benzinga.com/general/biotech/25/03/44459637/novo-nordisk-to-pay-around-2-billion-for-obesity-drug-from-china-based-biotech">$2 billion deal</a> to acquire rights to a Chinese obesity drug from United Laboratories International, investors remain unimpressed. 
The treatment, UBT251, is designed to challenge Eli Lilly &amp; Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) &#8216;Triple G&#8217; obesity drug, retatrutide, which has already shown promising weight loss results, <a href="https://www.cnbc.com/2025/03/25/healthy-returns-novo-nordisk-buys-united-laboratories-obesity-drug.html">reported</a> CNBC.
But with UBT251 still in early-stage trials, Lilly's blockbuster could hit the market first, leaving Novo Nordisk playing catch-up.
<h2 class="wp-block-heading">Trouble Ahead?</h2>
Novo Nordisk's weight loss empire is facing pressure on multiple fronts—technical signals scream bearish, competition is heating up, and Wall Street is questioning whether the company can maintain its dominance. 
As investors digest the latest drug deal, Novo Nordisk stock bulls may need more than a new obesity treatment to revive the stock's momentum. For now, the trend remains sharply downward.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/03/44490348/exclusive-vivani-medical-subdermal-semaglutide-implant-shows-20-weight-loss-in-animal-study-with-potential-for-once-yearly-dosing" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing</a></li>
</ul>
Image: Shutterstock

Health Care

Technicals

Signals

Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?

Active traders have new, highly powered tools at their disposal as Direxion rolls out four single-stock <a href="https://www.benzinga.com/topic/leveraged-etfs">leveraged and inverse exchange-traded funds.</a> 
These ETFs, focused on Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>), offer traders a way to multiply their bets—or hedge against downturns—in the booming pharmaceutical and cybersecurity sectors.
The latest additions include:
<ul>
<li>The Direxion Daily LLY Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELIL#NASDAQ">ELIL</a>)</li>
<li>Direxion Daily LLY Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELIS#NASDAQ">ELIS</a>)</li>
<li>The Direxion Daily PANW Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALU#NASDAQ">PALU</a>) and </li>
<li>Direxion Daily PANW Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALD#NASDAQ">PALD</a>).</li>
</ul>
Read Also: <a href="https://www.benzinga.com/markets/25/03/44451449/china-courts-apple-pfizer-eli-lilly-amid-us-pressure-vice-premier-says-beijing-will-continue-to-improve-the-business-environment">China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing &#8216;Will Continue To Improve The Business Environment&#8217;</a>
<h2 class="wp-block-heading">Why Eli Lilly, Palo Alto Networks?</h2>
According to Direxion CEO Douglas Yones, these two stocks are prime candidates for leveraged trading given Eli Lilly's dominance in healthcare innovation and Palo Alto Networks' leading position in cybersecurity. 
The ETFs allow traders to play short-term moves in these stocks with amplified exposure &#8211; ideal for those looking to capitalize on momentum or protect against volatility.
Recent performance highlights the appeal: Eli Lilly has gained 9.99% in the past year but slid 6.85% over the last month, while Palo Alto Networks has soared 32.51% year-over-year and held a modest 0.21% gain in the past month.
<h2 class="wp-block-heading">High Risk, High Reward</h2>
While these ETFs open up fresh opportunities, they are not designed for buy-and-hold investors. Leveraged and inverse funds are built for short-term trading strategies and come with increased risk. Unlike traditional ETFs, these products track a single stock rather than an index, making them highly volatile.
For traders with a high-risk tolerance, Direxion's latest ETFs offer a way to trade fast-moving stocks with leverage. Just make sure to understand the risks before diving in.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44463078/buy-the-dip-strategy-amid-market-chaos-why-a-billion-dollar-fund-is-buying-these-four-stocks">Buy-the-Dip Strategy Amid Market Chaos: Why A Billion Dollar Fund Is Buying These Four Stocks</a></li>
</ul>
Image: Shutterstock

Specialty ETFs

New ETFs

Tech

ETFs

ELIL

ELIS

PALD

PALU

PANW

Eli Lilly, Palo Alto Networks Traders Take Note: Direxion's New Leveraged ETFs Are Here

Everybody loves a great growth stock. We all know the stories of the incredible wealth delivered by fast-growing companies that keep growing for a long period of time.
Fortunes have been made by investors who correctly selected the best growth stocks and stayed invested for a long period of time regardless of economic changes and market gyrations.
With a seemingly endless supply of news and gyrations, as we start 2025, this is one of the most important lessons we can learn from market history.
Of course, finding and holding a great growth stock is not that easy.
For every Amazon, there are a dozen Pet.Coms, eToys and Webvans.
For every Bill Gates and Steve Jobs, there are thousands of others whose stabs at technological greatness are still in a box of useless junk in the back of a garage.
Here's a new tool to help you find the growth stocks that will last.
It is not enough to find these great companies to earn massive returns. You have to hold on through the market&#8217;s ups and downs and the endless wave of BS that the media will throw at the company over the years.
In bear markets, these stocks can get crushed.
Investors who are confident enough to not just hold on but buy more stand to make the kind of gains most people only dream about.
There is a reason that very few people make as much as they should off these great growth stocks.
Finding them and then holding them for a long time is hard to do.
This is where the new <a href="https://www.benzinga.com/screener/top-growth-stocks">Benzinga growth ranking</a> can help you become a better growth stock investor.
I designed these ratings to help identify companies with strong long-term growth prospects.
These companies are selling more of their products and services and seeing profits grow along with revenues. 
We are not looking for flash in the pan one hit wonder stocks. We want those that have been growing sales and profits and are likely to continue to do so.
Here are five companies that receive high grades from the Benzinga ranking system for growth right now:
Corporación América Airports S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAAP#NYSE">CAAP</a>) operates a portfolio of airports across Latin America and Europe, with its crown jewel assets in Argentina. This is a textbook example of an emerging market infrastructure play with monopolistic tendencies. CAAP controls hard-to-replicate assets that directly benefit from long-term air traffic growth, tourism recovery and currency normalization.
Despite facing Argentina&#8217;s well-documented macro risks, the business has turned the corner operationally, with international diversification and cost controls setting the stage for margin expansion.
Historically, CAAP&#8217;s sales have been cyclical, heavily impacted by Argentina&#8217;s economy and global air travel disruptions like the pandemic. Revenues collapsed in 2020 but have since rebounded sharply, with 2023 sales surpassing pre-pandemic levels. Earnings have been volatile but are stabilizing, with 2023 showing significant EBITDA growth and a return to profitability. The current trajectory suggests a multi-year upside if Argentina&#8217;s economy doesn&#8217;t implode.
Blue Bird Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>), the oldest U.S. school bus maker, has methodically pivoted into electric vehicles. While the core business is solid, the real story is the company&#8217;s leadership in EV school buses. With government funding pouring in and school districts warming up to electrification, Blue Bird is grabbing market share.
It's not flashy, but it is predictable and levered to a secular trend.
Blue Bird&#8217;s sales have historically been steady, reflecting school district budget cycles. Earnings were thin for years, but recent federal incentives for EV buses have ignited a surge in revenue and profits. Fiscal 2023 saw record sales and a massive jump in adjusted EBITDA, driven by higher pricing power and EV penetration. The company now boasts a record backlog, setting the table for continued growth.
NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has transformed from a graphics chip designer into the undisputed leader of AI infrastructure. The company&#8217;s GPUs are now essential tools for training large AI models, creating a near-insurmountable moat. Its data center segment has become the primary growth engine, dwarfing the original gaming business. NVIDIA is the shovel seller in the AI gold rush and it sells every shovel it can make.
Historically, NVIDIA has delivered incredible top-line and bottom-line growth, particularly over the past five years. Revenue soared from $11 billion in 2019 to over $60 billion in 2024, with margins expanding alongside. EPS has followed suit, driven by both sales growth and operating leverage. The recent AI boom has supercharged growth, with triple-digit year-over-year revenue increases in recent quarters.
Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has morphed into a pharmaceutical juggernaut, thanks largely to its success in diabetes and obesity treatments. Drugs like Mounjaro and Zepbound are redefining the market with massive commercial potential.
Combine that with a robust pipeline and Lilly&#8217;s execution, and you&#8217;ve got a healthcare powerhouse that&#8217;s just getting warmed up.
Historically, Lilly has grown revenue steadily, but the last three years have accelerated thanks to its metabolic drugs. Sales crossed $40 billion in 2023, up from $22 billion five years prior. Earnings have also exploded, with operating margins expanding due to high-margin drug sales.
The company&#8217;s forward growth outlook remains extremely strong.
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) is a unique software player, originally built for government intelligence and defense but is now making serious inroads into commercial markets.
Palantir&#8217;s platforms are sticky, complex, and mission-critical, which translates into strong pricing power and customer retention.
Historically, Palantir has posted consistent revenue growth north of 20% annually since going public. Sales have risen from $743 million in 2019 to over $2 billion in 2023. The company struggled with profitability early but recently posted GAAP profits, signaling a shift toward scale. Margins are improving as commercial contracts ramp, offering a compelling long-term growth story.
Earnings and sales growth across this group are either strong or downright explosive.
CAAP is rebounding nicely as air traffic picks up and Latin American economies stabilize, with recent double-digit revenue growth.
Blue Bird is riding the EV wave, posting record sales and margins as its backlog grows.
NVIDIA is simply a rocket ship, with sales and profits more than doubling as AI demand soars.
Eli Lilly is hitting its stride with obesity drugs, driving top and bottom-line growth at a blistering pace. Palantir is scaling into profitability while maintaining impressive revenue growth, setting up years of compounding ahead.
Simply put, these are companies in the right place at the right time, and the runway for continued growth looks wide open.
Finding Undervalued Stocks &amp; Managing Risk in a Volatile Market
Live on Tuesday, March 25, at 6 PM ET: Learn how to identify undervalued stocks with strong credit, protect your trades with options and take advantage of prime opportunities in today's volatile market with Tim Melvin, Ryan Faloona and Anne-Marie Baiynd. 
Register <a href="https://benzinga.zoom.us/webinar/register/WN_OJ2FBspHSJSSVNlW8zGapw">HERE</a> —spots are limited!
Photo: Shutterstock

Large Cap

Opinion

BLBD

CAAP

NVDA

PLTR

5 Stocks That Could Be The Next Nvidia

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly.
Looking at options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $203,125 and 5, calls, for a total amount of $303,548.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $600.0 to $890.0 for Eli Lilly over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale trades within a strike price range from $600.0 to $890.0 in the last 30 days. 
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742824902_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$12.3</td>
<td>$11.5</td>
<td>$12.08</td>
<td>$845.00</td>
<td>$97.1K</td>
<td align="right">287</td>
<td align="right">107</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/28/25</td>
<td>$10.5</td>
<td>$9.0</td>
<td>$9.67</td>
<td>$840.00</td>
<td>$96.5K</td>
<td align="right">467</td>
<td align="right">101</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$72.2</td>
<td>$71.1</td>
<td>$72.2</td>
<td>$880.00</td>
<td>$72.2K</td>
<td align="right">292</td>
<td align="right">1</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$131.15</td>
<td>$126.8</td>
<td>$128.0</td>
<td>$840.00</td>
<td>$64.0K</td>
<td align="right">15</td>
<td align="right">5</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$90.9</td>
<td>$86.75</td>
<td>$86.75</td>
<td>$840.00</td>
<td>$43.3K</td>
<td align="right">643</td>
<td align="right">2</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of Eli Lilly</h3>
<ul>
<li>Trading volume stands at 186,963, with LLY's price up by 1.03%, positioned at $846.22.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 38 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Eli Lilly, which currently sits at a price target of $1100. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Eli Lilly Unusual Options Activity

On Sunday, Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Cargill, and other major firms.
What Happened: "China will continue to improve the business environment and welcome more investment by multinational companies in China, sharing opportunities for development," he told the leaders, describing the country's economy as "highly resilient" and "full of vitality."
Executives from medical device maker Medtronic PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and investment management firm Conning were also in attendance, reported Reuters, citing a statement from China's Ministry of Commerce.
However, the statement did not specify where the meeting took place.
Many of the executives are in Beijing to attend the China Development Forum, where further high-level meetings, including a possible session with President Xi Jinping, are expected later this week, the report noted, citing unnamed sources.
See Also:&nbsp;<a href="https://www.benzinga.com/25/03/44272657/alibaba-chairperson-says-everyone-is-concerned-about-tariffs-as-he-expects-levies-on-chinese-evs" target="_blank" rel="noreferrer noopener">Alibaba's Joseph Tsai Says ‘Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs</a>
Why It's Important: Beijing has ramped up efforts to attract foreign capital amid a slowing economy and fresh <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">U.S. tariff headwinds</a> under President Donald Trump.
While American companies made up the largest group at this year's forum, sources say fewer U.S. CEOs attended compared to last year—signaling ongoing caution in cross-border corporate relations, the report noted.
Previously, the Chinese President expressed concerns about the possibility of China facing isolation similar to the Soviet Union during the Cold War. The ongoing trade war has heightened <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">fears of economic isolation</a>.
 Despite these challenges, <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production">China remains a leader</a> in technological advancements, particularly in artificial intelligence and robotics, according to investor Ray Dalio.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon's ‘Beast Games'—Now He's Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Economics

Media

AAPL

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

<a href="https://www.cnbc.com/2025/03/21/zepbound-copycats-tirzepatide-compounding-online-fda-ban.html">https://www.cnbc.com/2025/03/21/zepbound-copycats-tirzepatide-compounding-online-fda-ban.html</a>
<ul>
<li>Compounding pharmacies were largely supposed to stop making versions of tirzepatide this week, but it's still available on some popular websites like Amble, EllieMD, Willow and Mochi Health.</li>
<li>Pharmacies were able to make copycat versions of Eli Lilly's Zepbound and Mounjaro while the drugs were in shortage. But the FDA declared the shortage over late last year.</li>
<li>Mass compounding of Novo Nordisk's semaglutide — the active ingredient in Wegovy and Ozempic — is supposed to stop by the end of May.</li>
</ul>
This week was supposed to mark the end of <a href="https://www.cnbc.com/2024/12/24/fda-zepbound-shortage-impact-compounding-pharmacies-patients.html">compounding pharmacies</a> making copycat versions of <a href="https://www.cnbc.com/quotes/LLY/">Eli Lilly</a>'s weight-loss drug <a href="https://www.cnbc.com/2024/12/04/eli-lilly-zepbound-causes-more-weight-loss-than-novo-nordisk-wegovy-trial.html">Zepbound</a> and its diabetes drug Mounjaro. Online, it doesn't look like much has changed.&nbsp;
Popular websites like Amble, EllieMD, Willow and Mochi Health are all still advertising versions of tirzepatide, the active ingredient in Zepbound. Some, like Ivim, have stopped taking new patients.
&nbsp;
Mochi Health has no plans to stop, and neither do the four pharmacies it uses to supply patients with the medications, said Mochi CEO Myra Ahmad. The company uses a network of about 500 providers to write prescriptions for weight-loss drugs, including compounded versions. It's betting that offering personalized versions of the drugs will keep the company out of the crosshairs.&nbsp;
"It can be different dosing schedules … some patients prefer to go up in dosage much more slowly," Ahmad said. "Some patients like to mix a number of other medications into their compounded formulations, depending on the side effects that they're having. Some patients have side effects with any additives and brand name formulations. Compounding really opens up the door for so much personalization."&nbsp;
Amble, EllieMD and Willow didn't respond to CNBC's request for comment.&nbsp;
Compounding is where pharmacies mix ingredients of a drug to create a specialized version for specific patients. Say someone is allergic to a dye in a branded medication or needs a liquid form and the main manufacturer only sells capsules. In that case, the patient can turn to a compounded version.
When drugs are in shortage, they can be compounded in larger quantities to help fill the gap.&nbsp;
&nbsp;
Copycat versions of Lilly's Mounjaro and Zepbound and <a href="https://www.cnbc.com/quotes/NVO/">Novo Nordisk</a>'s Wegovy and Ozempic have been <a href="https://www.cnbc.com/2025/02/21/fda-shortage-of-novo-nordisks-wegovy-and-ozempic-drugs-is-resolved.html">widely available</a> in recent years because the U.S. Food and Drug Administration listed the brand versions as being in short supply.&nbsp;
That created a booming business for pharmacies compounding the highly popular class of weight loss and diabetes medications called <a href="https://www.cnbc.com/2024/05/14/healthy-returns-1-in-8-adults-have-taken-glp-1s-like-ozempic-survey.html">GLP-1s</a>.
But late last year, the FDA said all doses of Mounjaro and Zepbound were readily available and took the drug off its shortage list, spelling the end for mass compounding of the drug. After months of legal challenges, the FDA gave smaller pharmacies until early March to stop and larger pharmacies until this week before it started enforcing its rules.
The larger facilities aren't allowed to compound tirzepatide at all anymore. Smaller ones aren't supposed to make products that are essentially copies of a commercially available drug, a moniker with some wiggle room. The FDA sees essential copies as those that have a dosage within 10% of the commercially available drug or combine two or more commercially available drugs.
Mochi insists all of its prescriptions are personalized, including doses that differ from the standard Zepbound strengths. Other websites like EllieMD are advertising tirzepatide mixed with vitamin B12.&nbsp;
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, said formulations or dosage strengths that aren't commercially available aren't considered a copy. However, combining two drugs into one — like adding vitamin B6 or B12 — would be considered a copy under a strict reading of FDA guidance.&nbsp;
"FDA guidance are pretty clear about what is and is not a copy," Brunner said. "And I would say any compounding pharmacy or outsourcing facility that continues to prepare copies of tirzepatide injection after today are putting themselves in a certain amount of legal risks."&nbsp;
John Herr, pharmacist and owner of Town &amp; Country Compounding Pharmacy, stopped compounding tirzepatide earlier this month. He didn't want to take the risk even though his 300 to 400 patients on it have been calling nonstop to complain about losing access.
Town &amp; Country, based in Ramsey, New Jersey, was charging patients about $200 a month — about one-fifth the list price for Zepbound and less than half the price Lilly charges self-paying patients.&nbsp;
What happens next is an open question. Enforcing the ban on mass compounding of tirzepatide mostly falls to the FDA. The agency didn't immediately respond to CNBC's request for comment.
Lilly can try to sue companies that continue, but it hasn't had much luck in the past. A Florida judge last year <a href="https://www.biospace.com/lilly-suffers-legal-loss-in-tirzepatide-case-against-compounding-pharmacy">dismissed</a> one of Lilly's cases, saying the company was trying to enforce a law that only the FDA can.&nbsp;
Ahmad, the CEO of Mochi, said she isn't worried about Lilly taking legal action against her providers. The way she sees it, they have established patient-physician relationships with the autonomy to decide how best to manage their patients.
The next two months will be informative. Mass compounding of <a href="https://www.cnbc.com/2025/02/21/fda-shortage-of-novo-nordisks-wegovy-and-ozempic-drugs-is-resolved.html">semaglutide</a> — the active ingredient in Novo Nordisk's Ozempic and Wegovy — needs to stop by the end of May, according to the FDA.
<a href="https://www.cnbc.com/quotes/HIMS/">Hims &amp; Hers Health</a> has already <a href="https://x.com/AndrewDudum/status/1896339552127824255">said</a> it will stop selling commercially available doses of semaglutide when the time comes. Customers who have a personalized dosing regimen will be able to continue without any change, the company added.&nbsp;

'Zepbound Copycats Remain Online Despite FDA Ban' - CNBC

Eli Lilly &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading higher Thursday after the company launched its weight-loss drug <a href="https://www.benzinga.com/25/03/44326547/visa-eli-lilly-blackstone-and-a-real-estate-stock-on-cnbcs-final-trades">Mounjaro in India.</a>
What To Know: According to Reuters, Mounjaro, also known as tirzepatide, is now available in India at 4,375 rupees ($50.67) for a 5-milligram vial and 3,500 rupees ($40.54) for a 2.5-milligram vial. The pricing is significantly lower than in the United States, where the drug carries a list price of over $1,000 per fill. Analysts note that while Lilly gains a first-mover advantage over Novo Nordisk's Wegovy, the cost remains high for the Indian market. A patient on the highest dose would need to spend nearly 700,000 rupees ($8,100) annually, limiting accessibility for many consumers.
Novo Nordisk has already secured approval for Wegovy in India but has not yet set a launch date. Originally, the company planned for a 2026 release, but its India team is pushing for an earlier debut in 2025. The delay gives Lilly a competitive edge, at least in the short term, as demand for weight-loss treatments continues to rise.
India faces a growing public health challenge with obesity and diabetes rates steadily climbing. According to the International Diabetes Federation, the number of adults with diabetes in the country is expected to rise from 74.2 million in 2021 to over 124 million by 2045. A government survey found that nearly a quarter of Indian men and women between ages 15 and 49 are now overweight or obese, a notable increase from previous years.
While Novo Nordisk and Eli Lilly dominate the global GLP-1 receptor agonist market, which includes drugs like Wegovy, Ozempic and Mounjaro, competition is emerging from Indian pharmaceutical firms such as Sun Pharma, Cipla, Dr. Reddy's, and Lupin. These companies are working on developing generic versions to capture a share of what is projected to be a $150 billion global market within the next decade.
LLY Price Action: Eli Lilly shares are up 0.96% at $845.12 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2"><img loading="lazy" decoding="async" width="1024" height="530" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20151727/Screenshot-2025-03-20-at-15.17.05-1024x530.png" alt="" class="wp-image-834618" style="width:448px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20151727/Screenshot-2025-03-20-at-15.17.05-1024x530.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20151727/Screenshot-2025-03-20-at-15.17.05-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20151727/Screenshot-2025-03-20-at-15.17.05-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/20151727/Screenshot-2025-03-20-at-15.17.05.png 1533w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44421844/wall-street-holds-steady-buffetts-berkshire-hathaway-notches-record-highs-oil-surges-whats-driving-markets-thursday">Wall Street Holds Steady As Buffett&#8217;s Berkshire Hathaway Notches Record Highs: What&#8217;s Driving Markets Thursday?</a></li>
</ul>
Image Via Shutterstock.

Movers

Eli Lilly Shares Are Up Today: What's Going On?

WIIM

Eli Lilly shares are trading higher after the company reportedly launched weight loss drug Mounjaro in India at $50 for a 5mg vial.

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-launches-weight-loss-drug-mounjaro-india-after-drug-regulator-approval-2025-03-20/#:~:text=HYDERABAD%2C%20March%2020%20(Reuters),rates%20of%20obesity%20and%20diabetes.

Global

Reported Earlier: "Eli Lilly Launches Weight-Loss Drug Mounjaro In India At $50 For 5mg Vial, Beating Novo Nordisk" - Reuters News

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with LLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 26 uncommon options trades for Eli Lilly.
This isn't normal.
The overall sentiment of these big-money traders is split between 30% bullish and 53%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $82,216, and 24 are calls, for a total amount of $1,231,527.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $600.0 to $1120.0 for Eli Lilly over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Eli Lilly's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Eli Lilly's substantial trades, within a strike price spectrum from $600.0 to $1120.0 over the preceding 30 days.
<h3>Eli Lilly Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742480234_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.65</td>
<td>$15.85</td>
<td>$15.85</td>
<td>$835.00</td>
<td>$128.9K</td>
<td align="right">908</td>
<td align="right">221</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.75</td>
<td>$15.5</td>
<td>$16.05</td>
<td>$840.00</td>
<td>$123.8K</td>
<td align="right">838</td>
<td align="right">422</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$20.05</td>
<td>$18.15</td>
<td>$18.7</td>
<td>$835.00</td>
<td>$112.8K</td>
<td align="right">908</td>
<td align="right">383</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$19.5</td>
<td>$18.45</td>
<td>$18.7</td>
<td>$870.00</td>
<td>$93.5K</td>
<td align="right">553</td>
<td align="right">131</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$135.6</td>
<td>$129.35</td>
<td>$133.24</td>
<td>$840.00</td>
<td>$66.6K</td>
<td align="right">5</td>
<td align="right">5</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Following our analysis of the options activities associated with Eli Lilly, we pivot to a closer look at the company's own performance.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>With a volume of 324,237, the price of LLY is up 1.72% at $851.42. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 42 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Eli Lilly, targeting a price of $1100. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Eli Lilly options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Behind the Scenes of Eli Lilly's Latest Options Trends

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) revealed 17 unusual trades.
Delving into the details, we found 52% of traders were bullish, while 41% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $374,400, and 15 were calls, valued at $1,043,500.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $660.0 to $1240.0 for Eli Lilly over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Eli Lilly's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Eli Lilly's significant trades, within a strike price range of $660.0 to $1240.0, over the past month.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1742219169_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$89.0</td>
<td>$89.0</td>
<td>$89.0</td>
<td>$880.00</td>
<td>$267.0K</td>
<td>1.2K</td>
<td align="right">44</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$150.3</td>
<td>$148.0</td>
<td>$148.0</td>
<td>$720.00</td>
<td>$222.1K</td>
<td>13</td>
<td align="right">7</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$74.0</td>
<td>$71.8</td>
<td>$74.0</td>
<td>$800.00</td>
<td>$148.0K</td>
<td>673</td>
<td align="right">21</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$150.3</td>
<td>$148.35</td>
<td>$148.35</td>
<td>$720.00</td>
<td>$118.6K</td>
<td>13</td>
<td align="right">30</td>
</tr>
<tr>
<td>LLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$89.5</td>
<td>$89.5</td>
<td>$89.5</td>
<td>$880.00</td>
<td>$107.4K</td>
<td>1.2K</td>
<td align="right">13</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly's Current Market Status</h3>
<ul>
<li>With a trading volume of 116,120, the price of LLY is up by 0.48%, reaching $817.36.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 45 days from now.</li>
</ul>
<h3>Expert Opinions on Eli Lilly</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $1100.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Eli Lilly, maintaining a target price of $1100. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

This Is What Whales Are Betting On Eli Lilly

On Friday, CVS Health&nbsp;Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) released data from the CVS Weight Management&nbsp;program, in which participants achieved more than 15% weight loss on average. This included existing anti-obesity medication users who succeeded in nearly doubling their pre-program weight loss while working with program clinicians <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">on diet and lifestyle</a>.
Results are derived from a population of 265,000 members from 2023-2024.&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43709040/cvs-health-gains-momentum-after-q4-performance-analyst-upgrades-stock" rel="noreferrer noopener">CVS Health Gains Momentum After Q4 Performance, Analyst Upgrades Stock</a>
The initial results demonstrate improved weight loss and high program satisfaction for CVS Caremark clients&#8217; plan members trying a lifestyle-first approach, as well as additional clinical effectiveness and cost savings for members receiving clinical support while taking weight management <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/n44324587/cvs-weight-management-program-improves-health-outcomes-while-also-lowering-costs" rel="noreferrer noopener">medications like GLP-1s</a>.
GLP-1 products from Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) and Eli Lilli And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) have gained substantial traction. The CVS Weight Management program provides one-on-one support from a dedicated registered dietitian in a virtual setting, including personalized nutrition planning.
The program can integrate into a member&#8217;s existing pharmacy benefit with plan sponsors&#8217; direction.
CVS Caremark clients who adopted the CVS Weight Management program spent up to 26% less on&nbsp;GLP-1&nbsp;medications for weight loss than clients who did not adopt the program.
The program also has a lasting impact, with 92% of participating plan members expressing satisfaction after six months.
As of&nbsp;February 1, 2025, the CVS Weight Management program is now available to over 3.5 million CVS Caremark plan members.
Despite FDA prescription drug labeling recommendations to take&nbsp;GLP-1&#8217;s in combination with diet and physical activity, 70% of members were using a weight management drug without any lifestyle or nutrition support before enrolling in the CVS Weight Management program.
<ul>
<li>Before program enrollment, nearly 30% of members had lost less than 1% of their body weight on anti-obesity medication. These same members lost, on average, 11.7% of body weight after enrollment.</li>
<li>The program accelerated weight loss and delivered an average of 20% weight loss for those with moderate success before enrollment.</li>
<li>Members who chose to discontinue anti-obesity medication and retain lifestyle support maintained 94% of their weight loss after 6 months.</li>
</ul>
Price Action: CVS stock is up 1.33% at $66.64&nbsp;at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/03/44313315/perspective-therapeutics-cancer-focused-radiotherapy-portfolio-has-upside-potentional-says-analyst" target="_blank" rel="noreferrer noopener">Perspective Therapeutics&#8217; Cancer-Focused Radiotherapy Portfolio Has Upside Potential, Says Analyst</a></li>
</ul>
Photo via Shutterstock

CVS Weight Management Program Yields 15% Average Weight Loss, 26% Cost Saving Among Participants

Altimmune Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) hosted a virtual R&amp;D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">for pemvidutide</a>.
Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively.
Altimmune <a href="https://investorday.altimmune.com/presentation" target="_blank" rel="noreferrer noopener">anticipates</a> pemvidutide will reduce alcohol cravings, improve liver health and promote weight loss.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41296978/novo-nordisk-eli-lilly-could-face-downward-pressure-despite-market-dominance-from-p" rel="noreferrer noopener">Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names</a>
<ul>
<li>The primary <a href="https://investorday.altimmune.com/static-files/95c517e2-36ee-4427-9278-2d87cc4c1460" target="_blank" rel="noreferrer noopener">endpoint</a> for the Phase 2 ALD study will be a change in liver stiffness measurement at 24 weeks, with other key endpoints of weight loss and change in alcohol consumption, with an additional <a href="https://www.benzinga.com/news/24/06/39456224/altimmune-stock-is-rising-monday-whats-driving-the-action" target="_blank" rel="noreferrer noopener">reading at 48 weeks</a>.</li>
<li>The primary endpoint of the Phase 2 AUD study will be the change in the number of heavy drinking days at 24 weeks and the change in biomarkers of alcohol consumption and weight loss as secondary endpoints.</li>
</ul>
William Blair writes, &#8220;In our view, AUD and ALD are logical extensions for evaluation of pemvidutide&#8217;s efficacy, given its mechanisms of action.&#8221;
Altimmune shared the MOMENTUM Phase 2 trial data summary during the presentation, showing that over 30% of subjects lost ≥ 20% of body weight on pemvidutide 2.4 mg dose.
<ul>
<li>The lean mass ratio of lean body mass weight loss to total weight loss was 21.9% for pemvidutide in the Phase 2 MOMENTUM study, compared to 39.9% for semaglutide (based on Phase 3 STEP-1 trial data), 37.7% for retatrutide (from the Phase 2 study), and 26% for tirzepatide in the Phase 3 SURMOUNT 1 trial.</li>
</ul>
Novo Nordisk A/S&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) semaglutide is available as Wegovy and Ozempic and Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is available as Zepbound and Mounjaro.
The company says Phase 2b IMPACT trial results of pemvidutide for MASH are expected in the second quarter, and if successful, pemvidutide would become:
<ul>
<li>The first incretin-based agent to achieve statistical significance on fibrosis improvement at 24 weeks.</li>
<li>The first therapeutic candidate in any class to achieve statistically significant fibrosis improvement and meaningful weight loss at 24 weeks.</li>
<li>Altimmune expects to start registrational Phase 3 study in MASH in the first half of 2026</li>
</ul>
The presentation highlighted that at 24 weeks in the Phase 1b trial in metabolic dysfunction-associated steatotic liver disease (MASLD), pemvidutide demonstrated a 76.4% relative reduction in liver fat at the highest 2.4 mg dose (compared to 14% for placebo).
ALT Price Action: ALT stock is up 4.71% at $5.45 at publication Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44312852/needham-downgrades-dental-players-dentsply-sirona-zimvie-citing-weak-growth-outlook" target="_blank" rel="noreferrer noopener">Dental Players Dentsply Sirona, ZimVie Show Weak Growth Outlook: Analyst</a></li>
</ul>
Photo: Shutterstock

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/03/13/final-trades-visa-blackstone-eli-lilly-and-invitation-homes.html">Halftime Report Final Trades</a>,&#8221; Bryn Talkington of Requisite Capital Management said she loves Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and recommends buying the <a href="https://www.benzinga.com/quote/V/analyst-ratings">stock on the dip</a>.
The banking behemoth, on March 11, launched a new initiative aimed at tackling complex scams and preventing massive financial losses, per recent news. The company's newly formalized scam disruption practice, under its Visa Payment Ecosystem Risk and Control division, prevented over $350 million in attempted <a href="https://www.benzinga.com/25/03/44255550/whats-going-on-with-visa-stock-today">fraud in 2024 alone</a>.
Jason Snipe of Odyssey Capital Advisors said he likes Blackstone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>), which is down 20% year-to-date.
On Feb. 27, Blackstone disclosed that Rodney Zemmel – a long-time Senior Partner at McKinsey, who served as the global leader of both McKinsey Digital and the firm&#8217;s AI Transformation initiatives – was named Global Head of Portfolio Operations.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kevin Simpson of Capital Wealth Planning said Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has dominated the pharma space and momentum is not slowing down beyond weight loss as it has got a pipeline of Alzheimer's, oncology and autoimmune.
On March 7, Eli Lilly released new results from Ebglyss's (lebrikizumab-lbkz) long-term study, ADjoin. New data shows Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis (eczema) at three years.
Joshua Brown of Ritholtz Wealth Management named Invitation Homes Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVH#NYSE">INVH</a>) as his final trade.
Supporting his view, Mizuho analyst Haendel St. Juste, on March 13, upgraded the rating for Invitation Homes from Neutral to Outperform and increased the price target from $33 to $36.
Price Action:
<ul>
<li>Visa shares fell 1.3% to close at $328.55 on Thursday.</li>
<li>Blackstone fell 2.9% to settle at $136.53 during Thursday's session.</li>
<li>Eli Lilly declined 2.5% to close at $801.65 on Thursday.</li>
<li>Invitation Homes shares fell 0.6% to close at $32.89 on Thursday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/03/44300558/jim-cramer-arthur-j-gallagher-is-solid-this-industrial-company-is-fantastic">Jim Cramer: Arthur J. Gallagher Is &#8216;Solid,&#8217; This Industrial Company Is &#8216;Fantastic&#8217;</a></li>
</ul>
Photo: Shutterstock

Long Ideas

INVH

Visa, Eli Lilly, Blackstone And A Real Estate Stock On CNBC's 'Final Trades'

H.C. Wainwright &amp; Co. initiated coverage on Thursday for Perspective Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>), a clinical-stage biotechnology company advancing &#8220;targeted radiotherapy agents&#8221; for cancer treatment.
Analyst Robert Burns initiated a Buy rating and a <a href="https://www.benzinga.com/quote/CATX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $10</a>.
The company&#8217;s pipeline comprises:
<ul>
<li>VMT01/02 for melanoma, which is being studied as both monotherapy and in combination with Opdivo (nivolumab).</li>
<li>VMT-α-NET for various neuroendocrine cancers and other SSTR2-expressing tumors.</li>
<li>PSV359 for multiple solid tumor types.</li>
<li>PSV40X for prostate cancer.</li>
</ul>
The company&#8217;s melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for metastatic melanoma and neuroendocrine tumors.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
In January, Perspective Therapeutics&nbsp;revealed updated interim results from its ongoing Phase 1/2a trial of&nbsp;[212Pb]VMT-α-NET. Anti-tumor activities have been observed&nbsp;with a longer follow-up. As of the data cut-off date of Jan. 10, 2025, there were two unconfirmed responses and one confirmed response, <a href="https://www.benzinga.com/general/biotech/25/01/43197970/perspective-therapeutics-touts-encouraging-updated-data-from-gastrointestinal-cancer-trial-stock-soars" target="_blank" rel="noreferrer noopener">as in Cohort 2</a>.
H.C. Wainwright &amp; Co. writes that from a safety perspective, 212Pb-VMT-α-NET appears to be relatively benign at the dose levels tested thus far.
The analyst writes that PSV359 and VMT01/02 constitute upside potential. Burns also notes that in preclinical experiments, VMT01/02 demonstrated high response rates in multiple tested models and &gt;70% complete and durable response when combined with PD1 immunotherapy in a model highly resistant to checkpoint inhibitors
Perspective Therapeutics disclosed initial preclinical results for its FAPtargeted asset, PSV359 and views the preclinical anti-tumor efficacy as encouraging. The analyst also writes it is difficult to benchmark it against 177LuFAP-2286 and PNT6555 because these experiments were performed in a completely different mouse model.
&#8220;Additionally, when we think about potential targets for targeted radioligand therapy (TRT), we believe that most of the targets being pursued by ADCs and/or cell therapy are viable targets for TRT. As such, we view the targeted radioligand space as analogous to where the ADC space was a few years ago,&#8221; Burns writes.
Here are some M&amp;A in the radiopharmaceutical therapeutics&nbsp;space:
<ul>
<li>In 2023, Bristol Myers Squibb &amp; Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) acquired&nbsp;RayzeBio&nbsp;for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of&nbsp;<a href="https://www.benzinga.com/general/biotech/23/12/36382899/bristol-myers-squibb-takes-on-novartis-eli-lilly-with-rayzebio-4b-deal-in-radiopharmaceuticals" target="_blank" rel="noreferrer noopener">estimated cash acquired</a>.&nbsp;</li>
<li>In 2023, Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) acquired&nbsp;POINT Biopharma Global for $12.50 per share in cash, an aggregate of&nbsp;<a href="https://www.benzinga.com/general/biotech/23/10/35060421/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today" target="_blank" rel="noreferrer noopener">approximately $1.4 billion</a>.</li>
<li>In 2024, AstraZeneca Plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) acquired&nbsp;Fusion Pharmaceuticals for $21 per share in cash plus a non-transferable contingent value right of $3 per share in cash payable upon the achievement of a&nbsp;<a href="https://www.benzinga.com/general/biotech/24/03/37818128/astrazenecas-2-4b-fusion-pharmaceuticals-acquisition-signals-shift-in-efforts-from-traditional-re" target="_blank" rel="noreferrer noopener">specified regulatory milestone</a>.</li>
</ul>
CATX Price Action: Perspective Therapeutics stock is down 0.75% at $2.64 at publication Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/03/44306287/village-farms-ceo-highlights-momentum-for-profitable-expansion-clocks-11-jump-in-q4-sales" target="_blank" rel="noreferrer noopener">Village Farms CEO Highlights Momentum For Profitable Expansion, Clocks 11% Jump In Q4 Sales</a></li>
</ul>
Photo: S_fam photo via Shutterstock

Analyst Color

Initiation

CATX

Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst

CNBC Halftime Report Final Trades: Visa, Blackstone, Eli Lilly and Company, Invitation Homes

<a href="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions" title="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions">https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions</a>

Legal

'Telehealth Platforms In Senators' Crosshairs Over Relationship With Eli Lilly, Pfizer; In Letters, Lawmakers Question If Direct-To-Consumer Deals Could Influence Prescriptions' - STAT News

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$35.00</td>
<td>$43.0K</td>
<td>680</td>
<td>1.7K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/14/25</td>
<td>$815.00</td>
<td>$26.5K</td>
<td>38</td>
<td>268</td>
</tr>
<tr>
<td>BMY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$62.50</td>
<td>$125.9K</td>
<td>90</td>
<td>253</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$360.00</td>
<td>$119.2K</td>
<td>472</td>
<td>203</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$210.00</td>
<td>$95.5K</td>
<td>290</td>
<td>193</td>
</tr>
<tr>
<td>IQV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$180.00</td>
<td>$200.2K</td>
<td>31</td>
<td>111</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$490.00</td>
<td>$99.7K</td>
<td>92</td>
<td>77</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$165.00</td>
<td>$26.6K</td>
<td>6.1K</td>
<td>56</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$330.00</td>
<td>$80.8K</td>
<td>14</td>
<td>29</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$600.00</td>
<td>$101.9K</td>
<td>0</td>
<td>10</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a call option trade that happens to be bullish, expiring in 37 day(s) on April 17, 2025. This event was a transfer of 426 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $43.0K, with a price of $101.0 per contract. There were 680 open contracts at this strike prior to today, and today 1750 contract(s) were bought and sold. 
• For LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we notice a call option trade that happens to be neutral, expiring in 3 day(s) on March 14, 2025. This event was a transfer of 20 contract(s) at a $815.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $1325.0 per contract. There were 38 open contracts at this strike prior to today, and today 268 contract(s) were bought and sold. 
• For BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we notice a put option sweep that happens to be bearish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 221 contract(s) at a $62.50 strike. This particular put needed to be split into 13 different trades to become filled. The total cost received by the writing party (or parties) was $125.9K, with a price of $570.0 per contract. There were 90 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option trade that happens to be bearish, expiring in 10 day(s) on March 21, 2025. This event was a transfer of 200 contract(s) at a $360.00 strike. The total cost received by the writing party (or parties) was $119.2K, with a price of $596.0 per contract. There were 472 open contracts at this strike prior to today, and today 203 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a put option sweep that happens to be bullish, expiring in 31 day(s) on April 11, 2025. This event was a transfer of 193 contract(s) at a $210.00 strike. This particular put needed to be split into 16 different trades to become filled. The total cost received by the writing party (or parties) was $95.5K, with a price of $495.0 per contract. There were 290 open contracts at this strike prior to today, and today 193 contract(s) were bought and sold. 
• Regarding IQV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>), we observe a put option sweep with bullish sentiment. It expires in 283 day(s) on December 19, 2025. Parties traded 110 contract(s) at a $180.00 strike. This particular put needed to be split into 24 different trades to become filled. The total cost received by the writing party (or parties) was $200.2K, with a price of $1820.0 per contract. There were 31 open contracts at this strike prior to today, and today 111 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 23 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $99.7K, with a price of $4335.0 per contract. There were 92 open contracts at this strike prior to today, and today 77 contract(s) were bought and sold. 
• Regarding JNJ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), we observe a call option trade with bullish sentiment. It expires in 101 day(s) on June 20, 2025. Parties traded 35 contract(s) at a $165.00 strike. The total cost received by the writing party (or parties) was $26.6K, with a price of $760.0 per contract. There were 6139 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option trade that happens to be bullish, expiring in 192 day(s) on September 19, 2025. This event was a transfer of 26 contract(s) at a $330.00 strike. The total cost received by the writing party (or parties) was $80.8K, with a price of $3110.0 per contract. There were 14 open contracts at this strike prior to today, and today 29 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with neutral sentiment. It expires in 464 day(s) on June 18, 2026. Parties traded 10 contract(s) at a $600.00 strike. The total cost received by the writing party (or parties) was $101.9K, with a price of $10193.0 per contract. There were 0 open contracts at this strike prior to today, and today 10 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

VKTX

10 Health Care Stocks Whale Activity In Today's Session

Press Releases

Lilly to participate in Leerink Partners Global Healthcare Conference

Laekna Announces IND Approval of LAE120 (a Novel USP1 Inhibitor) for Treatment of Advanced Solid Tumors by FDA

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Contracts

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

Organovo Provides Business Update

Global Radiotherapy Market Expected to Reach $9.62 Billion By 2030 Realizing Growth Due to Technological Advancements

LillyDirect platform expands to facilitate access to Alzheimer's disease care

ATNM

AVIR

CARM

COYA

INCY

MEIP

RIBT

SYBX

TSX:PHO

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Wells Fargo

Truist Securities

Citigroup

B of A Securities

Wolfe Research

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Screenshot 2024-02-24 at 12.03.42 AM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Screenshot 2024-02-22 at 11.51.01 PM

BTTX

Better Therapeutics Follows Up Wins Including FDA Authorization For AspyreRx In 2023 With Securing FDA Breakthrough Device Designation Targeting Advanced Liver Disease

Comments

Eli Lilly

空売り

Eli Lilly (NYSE:LLY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル